(UroToday.com) In this session, Dr. Himisha Beltran discussed whether molecular markers can inform treatment decisions in mHSPC. She began by highlighting the as yet unmet clinical need for biomarkers to optimally select treatment for men with mHSPC. Specifically, biomarkers could help to select between therapies (ADT plus AR targeted agent versus docetaxel versus triplet therapy), select patients for therapy intensification versus deintensification, and monitor response.